Biotech

All Articles

GSK's long-acting breathing problem drug cut in half assaults in phase 3

.GSK's long-acting asthma therapy has been revealed to cut in half the number of attacks in a pair o...

AstraZeneca, Daiichi unload Dato-DXd's overall survival fall short

.AstraZeneca and Daiichi Sankyo's TROP2-directed antibody-drug conjugate (ADC) has actually stopped ...

Roivant unveils new 'vant' to evolve Bayer high blood pressure med

.Matt Gline is actually back with a brand new 'vant' provider, after the Roivant Sciences chief exec...

Viridian eye disease phase 3 hits, accelerating press to rivalrous Amgen

.Viridian Therapeutics' period 3 thyroid eye ailment (TED) scientific trial has actually attacked it...

Bain unveils $3B fund forever scientific research providers

.With a strong track record for identifying rough diamonds, Bain Funding Everyday Life Sciences (BCL...

Genentech's cancer restructure brought in 'for medical reasons'

.The latest decision to merge Genentech's two cancer departments was made for "clinical causes," man...

Tern oral GLP-1 shows 5% fat loss at 1 month at highest possible dose

.Terns Pharmaceuticals' choice to drop its liver illness passions might yet repay, after the biotech...

Merck, Daiichi replay early effectiveness in little mobile lung cancer with updated ADC data

.Merck &amp Co.'s long-running initiative to land a blow on little mobile bronchi cancer cells (SCLC...

Boehringer, Bayer innovation bronchi cancer drugs toward Astra struggle

.Some clients along with non-small cell lung cancer (NSCLC) have anomalies in a gene referred to as ...

MBX goes for $136M IPO to take opponent to Ascendis right into phase 3

.MBX has elaborated programs to absorb over $136 million coming from its own IPO as the biotech hope...